Brian T Chung1,2, Hsin-Yu Chen1, Jeremy Gordon1, Daniele Mammoli1, Renuka Sriram1, Adam Autry1, Lydia Le Page1,3, Myriam Chaumeil1,3, Peter Shin1, James Slater1, Chou T Tan4, Chris Suszczynski4, Susan Chang5, Robert Bok1, Sabrina Ronen1,2, Peder EZ Larson1,2, John Kurhanewicz1,2, and Daniel B Vigneron1,2
1Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, United States, 2UCSF – UC Berkeley Graduate Program in Bioengineering, University of California, San Francisco, CA, United States, 3Department of Physical Therapy and Rehabilitation Science, University of California San Francisco, San Francisco, CA, United States, 4ISOTEC Stable Isotope Division, MilliporeSigma, Merck KGaA, Miamisburg, OH, United States, 5Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, United States
We investigated hyperpolarized (HP) [2-13C]pyruvate conversion to
[2-13C]lactate and [5-13C]glutamate for the first time in the healthy human
brain, with a focus on the development of hyperpolarization and preparation techniques for sterile [2-13C]pyruvate with FDA-IND & IRB approval. HP
[2-13C]pyruvate, [2-13C]lactate, [5-13C]glutamate and other metabolites were
successfully observed and quantitatively measured for the first time in four
volunteers, and initial EPI studies confirmed a feasibility of imaging [2-13C]pyruvate to [5-13C]glutamate conversion, demonstrating a significant
first step for HP metabolic imaging to diagnose and detect early stage
neurological disorders.
